TrialNature medicine2026
An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial.
Xiaoxu Li et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
2 papers cite it
this papercites it
TrialNature medicine2026
Xiaoxu Li et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.